Thank you This live web event has ended. Thank you for attending. Contributors Christopher Worrall, Ph.D. Dr. Christopher P Worrall joined Nanoform as the Vice President of US Business Development in May 2021. He is an expert in the area of crystallization and physicochemical modification, having spent the last 14 years specializing in the pharmaceutical solid form, including 13 years with Pharmorphix. Dr. Worrall has been involved in the development of 7 commercial pharmaceutical products and is an inventor on numerous patents in the areas of liquid crystals, organic semi-conductors, and pharmaceutical solid form. Prior to 2008, he held scientist positions at SAFC and Merck KGaA focusing on developing organic syntheses for GMP production of active pharmaceutical ingredients and display materials. He earned his PhD in synthetic organic chemistry from the University of Manchester, UK, and has multiple publications in the areas of atropisomerism and enantioselective synthesis. Elisabetta Micelotta, Ph.D. Elisabetta Micelotta has extensive research experience within the fields of astrophysics and nanoscience in space, having completed a Marie Curie Postgraduate Fellowship at the Institut d’Astrophysique Spatiale in France and formerly holding a position of Postdoctoral Research Assistant at NASA Goddard. Elisabetta further progressed as a Researcher in the Department of Physics at the University of Helsinki. In her current role of Science and Technology Team Leader at Nanoform, Elisabetta’s work focuses on investigating the physico-chemical foundations of nanoformation to support continuous improvement of the process. In this perspective, Elisabetta’s team has developed STARMAP®, Nanoform’s AI-based tool to identify the candidate molecules best amenable to CESS®.